Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.

MLA

Chen, Wei, et al. “Risk of Clostridioides Difficile Infection in Inflammatory Bowel Disease Patients Undergoing Vedolizumab Treatment: A Systematic Review and Meta-Analysis.” BMC Gastroenterology, vol. 24, no. 1, Oct. 2024, p. 377. EBSCOhost, https://doi.org/10.1186/s12876-024-03460-z.

APA

Chen, W., Liu, Y., Zhang, Y., Zhang, H., Chen, C., Zhu, S., Zhou, Y., Zhao, H., & Zong, Y. (2024). Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis. BMC Gastroenterology, 24(1), 377. https://doi.org/10.1186/s12876-024-03460-z

Chicago

Chen, Wei, Yuhang Liu, Yuelun Zhang, Hong Zhang, Chuyan Chen, Siying Zhu, Yanhua Zhou, Haiying Zhao, and Ye Zong. 2024. “Risk of Clostridioides Difficile Infection in Inflammatory Bowel Disease Patients Undergoing Vedolizumab Treatment: A Systematic Review and Meta-Analysis.” BMC Gastroenterology 24 (1): 377. doi:10.1186/s12876-024-03460-z.